AB SCIENCE news, videos and press releases - Page 2
For more news please use our advanced search feature.
AB SCIENCE - More news...
AB SCIENCE - More news...
- AB Science has received approval from the U.S. Food and Drug Administration (FDA) to initiate the confirmatory Phase 3 study with masitinib in the treatment of progressive multiple sclerosis
- Masitinib receives orphan drug status for the treatment of amyotrophic lateral sclerosis in Switzerland
- AB Science announces the drawdown of the first tranche of 6 million euros under its financing agreement with the European Investment Bank
- AB Science receives first agencies authorizations to initiate confirmatory Phase 3 clinical study with masitinib in the treatment of Alzheimer’s disease
- AB Science today reports its revenues for the first half of 2022 and provides an update on its activities
- AB Science today announced publication of results from its positive study of masitinib in severe asthma uncontrolled by oral corticosteroids in the peer-reviewed Journal of Asthma and Allergy
- AB Science announces that Health Canada has started the review of New Drug Submission for masitinib in the treatment of ALS
- AB Science announces the financing of a 8.5 million dollars through the issuance of convertible bonds with attached warrants
- AB Science will host a live webcast on February 28, 2022 to provide details on the masitinib filing in the treatment ALS in Canada and to provide an update on its clinical program in all indications
- AB Science granted authorization to initiate confirmatory Phase III trial of masitinib in progressive forms of multiple sclerosis by the Swedish Medical Products Agency
- AB Science granted authorization to initiate confirmatory Phase III trial of masitinib in progressive forms of multiple sclerosis by the French Health Authority (ANSM)
- AB Science announces dosing of first patient in Phase 2 trial of masitinib’s antiviral activity against the SARS-CoV-2 (COVID-19) virus
- AB Science received FDA authorization to initiate Phase 1/II trial of AB8939 in the treatment of acute myeloid leukemia
- AB Science received authorization from the FDA to resume patient enrollment in the confirmatory Phase 3 study of masitinib (AB19001) in patients with ALS
- AB Science granted authorization from the French Health Authority (ANSM) to initiate a study of AB8939 in the treatment of Acute Myeloid Leukemia (AML)
- AB Science today reports its revenues for the first half of 2021 and provides an update on its activities
- AB Science receives regulatory authorization to commence a second Phase 2 Covid-19 study
- AB Science receives Health Canada approval letter to commence Phase I/II trial of AB8939 in the treatment of Acute Myeloid Leukemia (AML)
- AB Science announced that an abstract on the long-term survival of masitinib in ALS has been selected for a platform presentation at the Annual Meeting of the Spanish Society of Neurology
- AB Science announces that it has received a second authorization to resume patient enrollment, in the Phase 3 study of masitinib in mastocytosis
- AB Science publishes a Q&A press release, following-up on its June 28, 2021 press release relating to an agreement with historical shareholders
- AB Science announced that results from its Phase 3 AB09004 study on mild to moderate Alzheimer’s disease have been presented at the AAIC
- AB Science announces the publication of an article in the world-renowned journal Science that confirms potential of masitinib as a treatment of Covid-19 with anti-viral activity against SARS-CoV-2 and all tested variants of concern
- AB Science announces the publication of new survival data showing that masitinib extended survival in ALS by 25 months relative to placebo
- AB Science announces a voluntary hold in the clinical studies of masitinib worldwide
- AB Science will host a live webcast on Tuesday May 25, 2021 on masitinib results in Prostate Cancer
- AB Science reports today its annual financials as of 31 December 2020 and provides an update on its activities
- AB Science today announced that its masitinib Phase 2B/3 study (AB12003) in metastatic castrate-resistant prostate cancer (mCRPC) met its predefined primary endpoint
- AB Science secures 6M€ in non-dilutive financing guaranteed by the French Government
- AB Science provides an update on the expected timelines for the read-out of its masitinib Phase 3 study (AB12003) in metastatic castrate-resistant prostate cancer
